Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis

IDWeek 2014, Philadelphia, PA, October 8–12, 2014

Mark S. Sulkowski, MD, Kris Kowdley, MD, Peter J. Ruane, MD, Trevor Hawkins, MD, Richard Elion, MD, Kimberly Workowski, MD, Anthony Mills, MD, Mani Subramanian, MD, PhD, Xiao Ding, PhD, Star Seyedkazemi, PharmD, Robert H. Hyland, D.Phil, Jenny C. Yang, PharmD, Phillip S. Pang, MD, PhD, John G. Mchutchison, MD, Nezam Afdhal, MD and David Wyles, MD

EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study- (04/14/14)
EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study - (04/14/14)
EASL: Ledipasvir/Sofosbuvir With and Without Ribavirin for 8 Weeks Compared to Ledipasvir/Sofosbuvir for 12 Weeks in Treatment-Naïve Noncirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 ION-3 Study - (04/11/14)

USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 INFECTION IN PATIENTS COINFECTED WITH HIV (Interim results)…http://www.natap.org/2014/EASL/EASL_05.htm

Sovaldi\ledipasvir+vedroprevir Study in treatment-experienced gt1 cirrhotics - 8 weeks - (10/08/14)
Ledipasvir/Sofosbuvir HIV/HCV Coinfection Phase 3 Study Ongoing - (09/03/14)

NEJM

ION-1 Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection - (04/14/14)
ION-2 Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection - (04/14/14)
ION-3 Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis - (04/11/14)